Skip to search formSkip to main contentSkip to account menu

TD-4208

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Pharmacological properties of revefenacin (TD‐4208), a novel, nebulized long‐acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and…
Revefenacin (TD‐4208) is a novel, long‐acting, and lung‐selective muscarinic cholinergic receptor (mAChR) antagonist in… 
Review
2017
Review
2017
Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs
ABSTRACT Introduction: Long acting muscarinic receptor antagonists (LAMA) reverse airflow obstruction by antagonizing para… 
2014
2014
Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD
Introduction TD-4208 is a lung-selective, LAMA shown to have a long duration of action and minimal systemic antimuscarinic… 
2012
2012
A randomized, crossover study to examine the pharmacodynamics and safety of a new antimuscarinic (TD-4208) in COPD
Background: TD-4208 is a potent and selective inhaled muscarinic antagonist with functional lung selectivity and long duration in… 
2009
2009
TD-4208: A Novel, Lung-Selective Muscarinic Antagonist with Sustained Bronchoprotective Activity in Preclinical Models.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)